Fig. 5 

Resveratrol treatment alleviates motor dysfunction whilst simultaneously increasing acetylated histone and SIRT1 levels. A Mutant ataxin-3 zebrafish at 6 days post fertilization (dpf) showed a decrease in the distance swum (***p < 0.001) whilst resveratrol treatment (50 µM) from 1–6 dpf rescued this dysfunction, (*p = 0.0033, n = 45–71). B Immunoblot of vehicle versus resveratrol treated EGFP-Ataxin-3 84Q fish at 6 dpf showed increased SIRT1 levels following resveratrol treatment. C Quantification revealed that SIRT1 levels were increased by resveratrol (p = 0.003, n = 14). D Immunoblot of 6 dpf transgenic MJD zebrafish treated with or without resveratrol increases full-length (FL) human ataxin-3 levels. E Quantification of levels of acetylated H3K9 (ac-H3K9); F acetylated H4K5 (ac-H4K5); G FL ataxin-3; and H cleaved (CF) ataxin-3, revealed that resveratrol treatment produced no change in ac-H3K9 levels, an increase in ac-H4K5 (**p = 0.005), an increase in FL-ataxin-3 (*p = 0.018) and no change in cleaved ataxin-3 levels (n = 19, n = 19, n = 7 and n = 7 respectively). CF cleavage fragment, ZF zebrafish. Data represents mean ± SEM. Statistical analysis used for motor behaviour tracking was a one-way ANOVA followed by a Tukey post-hoc analysis and the immunoblot comparisons were analysed using a paired student t-test